Fernanda G. Herrera

Prof Rad-Onc, Chair Service of Radiation Oncology CHUV UNIL Lausanne. Passion for Immunology & Oncology. EORTC former Chair Gynecology Cancer Group. HerreraLab

[Fernanda G. Herrera @fg_herrera]

@rweichselbaum @DangajD We found amphiregulin in NR monocytes and NKs 😉

[Fernanda G. Herrera @fg_herrera]

1) Why do immune-excluded tumors resist immunotherapy?
T cells are there—but they can't effectively infiltrate the tumor. https://t.co/TGpkOo2vso
#RACIN tested whether #LDRT (1 Gy) could reprogram the #TME and unlock anti-tumor immunity. @DangajD

[Petrova Lab – Vascular and Tumor Biology @PetrovaLab]

Happy to share scRNA-seq dataset of murine mesenteric tissue in easy-to-use format at the Single Cell Portal
https://t.co/puER0Zxu8a

BECs, LECs, SMCs, fibroblasts, mesothelial cells from WT & Foxc2lecKO at single-cell resolution.

Original publication: https://t.co/c8FOh6qfUm

[Petrova Lab – Vascular and Tumor Biology @PetrovaLab]

Thank you very much Nicola Diny and @JCellBiol for highlighting our work on intestinal eosinophils !🙏

[Fernanda G. Herrera @fg_herrera]

12) Our deepest gratitude goes to the patients and their families, and to all collaborators, partners, clinicians, scientists, and study teams who made #RACIN possible. 🙏Our hospital and department. @FBM_UNIL @unil @CHUVLausanne

[Fernanda G. Herrera @fg_herrera]

11) This is a story that started at @CD_AACR with the publication of our 2022 work (DOI: 10.1158/2159-8290.CD-21-0003) and continues now in @CCR_AACR. We are deeply grateful to the editors and reviewers for their insightful comments and support throughout this journey.

[Shankar Siva @_ShankarSiva]

This is so cool!!! Thanks @TheLancetOncol #radonc

[Ralph Weichselbaum @rweichselbaum]

@DrSpratticus I’m in agreement and impressed by everything you say with the exception of handing out congratulations this is definitely not a home run. I’m not even sure I would’ve done this trial.

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Pierre Blanchard, MD @PBlanchardMD]

I really recommend this evidence based critical analysis of PROTEUS @NEJM article (available here: https://t.co/toJQjzucDi).

This is a big trial, but with many issues (control arm, primary endpoint, effect size...) that may not translate into meaningful patient benefit #ASCO26

[Fernanda G. Herrera @fg_herrera]

Grateful to @snsf_ch for supporting our research on #low_dose_RT through the 1 April 2025 project funding call 🙏. Excited to move this work forward with my team & collaborators! 🚀 Stay tuned more is coming #FLASH #research #LowDose #radiation @CHUVLausanne @fbm @OncoUNILCHUV